Canada - Engels - Health Canada

allergan inc - tazarotene - gel - 0.05% - tazarotene 0.05% - misc. skin and mucous membrane agents

Canada - Engels - Health Canada

allergan inc - tazarotene - gel - 0.1% - tazarotene 0.1% - misc. skin and mucous membrane agents

Canada - Engels - Health Canada

allergan inc - tazarotene - cream - 0.05% - tazarotene 0.05% - misc. skin and mucous membrane agents

Canada - Engels - Health Canada

allergan inc - tazarotene - cream - 0.1% - tazarotene 0.1% - misc. skin and mucous membrane agents

Verenigde Staten - Engels - NLM (National Library of Medicine)

bausch health us, llc - halobetasol propionate (unii: 91a0k1ty3z) (halobetasol - unii:9p6159hm7t), tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - duobrii® (halobetasol propionate and tazarotene) lotion, 0.01%/0.045% is indicated for the topical treatment of plaque psoriasis in adults. duobrii lotion is contraindicated in pregnancy [see warnings and precautions (5.1), use in specific populations (8.1, 8.3)]. risk summary based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, duobrii lotion may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. safety in pregnant females has not been established. the potential risk to the fetus outweighs the potential benefit to the mother from duobrii lotion during pregnancy; therefore, duobrii lotion should be discontinued as soon as pregnancy is recognized [see contraindications (4), warnings and precautions (5.1), clinical pharmacology (12.3)] . observational studies suggest an increased risk of low birthweight in infants with the maternal use of potent or very potent topical corticosteroids (see data ).  in an

Verenigde Staten - Engels - NLM (National Library of Medicine)

almirall, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps) - tazorac® (tazarotene) cream, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis. tazorac (tazarotene) cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris. tazorac cream is contraindicated in: - pregnancy. retinoids may cause fetal harm when administered to a pregnant female [see warnings and precautions (5.1), use in specific populations (8.1, 8.3)] . - individuals who have known hypersensitivity to any of its components [see warnings and precautions (5.2)] . risk summary based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, tazorac cream may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. safety in pregnant females has not been established. the potential risk to the fetus outweighs the potential benefit to the mother from tazorac cream during pregnancy; therefore, tazorac cream should be discontinued as soon as pregnancy is re

Canada - Engels - Health Canada

bausch health, canada inc. - tazarotene - lotion - 0.045% - tazarotene 0.045% - misc. skin and mucous membrane agents

Australië - Engels - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - tazarotene -

Verenigde Staten - Engels - NLM (National Library of Medicine)

sincerus florida, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4) -

Verenigde Staten - Engels - NLM (National Library of Medicine)

sincerus florida, llc - tazarotene (unii: 81bdr9y8ps) (tazarotene - unii:81bdr9y8ps), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) -